Astrana Health (ASTH) Q2 2026 Earnings Call Transcript
Astrana Health (ASTH) reported Q2 2026 revenue of $972.5M, up 49% YoY, and adjusted EBITDA of $68.9M, up 43%. Adjusted EPS was $0.80. Six-month free cash flow was $92.9M. The company reaffirmed full-year revenue guidance of $3.8B to $4.1B and raised adjusted EBITDA guidance to $255M to $280M. Net leverage was 2.26.
How this was made
The 30-second read
Why it matters
The most tradable elements are the updated full-year adjusted EBITDA range, reaffirmed revenue and free cash flow ranges, explicit Q3 guidance, and quantified risk levers (Medicaid attrition, medical cost trend, and one-time ACO REACH CMS billing adjustment).
Market read
Traders can update models using the raised adjusted EBITDA guidance and the provided Q3 revenue and EBITDA ranges, while monitoring Medicaid attrition and CMS billing adjustments as near-term volatility sources.
What to watch
The transcript emphasizes AI automation and synergy realization, but traders should scrutinize cohort maturity assumptions behind mid to high teens medium-term EBITDA growth and the sustainability of medical cost trend at 5.2% YTD.
Background
Astrana Health held its Q2 2026 earnings call, discussing results, integration progress from the Prospect Health acquisition, and guidance for Q3 and full-year 2026.
Ticker impact
Astrana Health reported Q2 2026 results and reaffirmed full-year revenue guidance $3.8B to $4.1B, raising adjusted EBITDA to $255M to $280M.
Bias modestly positive for the next few sessions as traders price in higher EBITDA/FCF guidance, with downside risk if Medicaid attrition or commercial cost trends worsen.
The article discloses multiple decision-relevant datapoints: raised adjusted EBITDA range, reaffirmed revenue and FCF ranges, net leverage down to 2.26, and explicit Q3 revenue and EBITDA guidance. Offsetting risks are also quantified (one-time $15M ACO REACH revenue reduction, Medicaid attrition tracking high end).
Market effects
Reinforces investor focus on AI-enabled operating leverage and risk-capitation mix shift (professional risk to full risk) as a driver of margin durability in value-based care.
Highlights California Medicaid eligibility redeterminations as a near-term headwind, while Medicare Advantage expansion in Hawaii and Texas supports membership stability.
Limited direct global impact; primarily affects US managed care and value-based care sentiment around CMS program execution and risk-adjusted returns.
Counterpoint
Raised EBITDA guidance may be partially offset by program-specific billing dynamics (ACO REACH CMS adjustments) and Medicaid attrition that could accelerate beyond management’s current expectations.
Key entities
- companyAstrana Health
Reported Q2 2026 revenue growth, improved leverage, and raised full-year adjusted EBITDA guidance while reaffirming revenue and free cash flow guidance.
- executiveBrandon Sim
CEO who discussed AI-native operating system, risk-capitation mix, and cost trend management.
- executiveChan Basho
CFO who detailed guidance drivers including the one-time ACO REACH CMS billing adjustment and synergy realization.
